2015 Towards an HIV Cure Symposium
18 & 19 July 2015 | Vancouver, Canada

Background

The IAS and the Towards an HIV Cure Stakeholder’s Advisory Board organized the fourth annual Towards an HIV Cure Symposium in Vancouver, Canada, on 18 & 19 July 2015, immediately preceding the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2015).

The symposium continued to showcase the latest research in HIV cure, but also provided a platform for presenting the progress of the initiative working groups and creating a fertile setting for dialogue with the broader community, through abstract driven sessions, poster exhibition sessions and roundtable discussions.

The symposium was co-chaired by Françoise Barré-Sinoussi, Director of the Regulation of Retroviral Infections Unit, Institut Pasteur, France, Steven Deeks, Professor of Medicine at the University of California, San Francisco (UCSF), United States, and Sharon Lewin, Director of the Doherty Institute for Infection and Immunity, University of Melbourne, Australia.

Symposium Objectives

  • Provide an opportunity for scientists who are working on HIV cure to share ideas, debate, and network among their peers;
  • Develop knowledge on the priorities that future research must address in order to tackle HIV persistence in patients on ART;
  • Accelerate research on viral reservoirs and latency as the way towards achieving a cure for HIV infection;
  • Promote increased investments in HIV/AIDS cure research;
  • Provide a platform for information-sharing between scientists, clinicians, funders, media and members of civil society.

2015 Symposium Programme Committee

With the support of:

Symposium material

  • Related documents
  • Day 1
  • Day 2
  • Poster Exhibition
  • Multimedia

Opening Session


Keynote Address: Progress and Challenges in HIV Cure Research
Daniel Kuritzkes, Brigham & Women’s Hospital, Harvard Medical School, United States

Presentation | Audio

Community Speaker: Community Involvement in HIV Cure-related Research: Not Just Guinea Pigs
Matthew Sharp, Long-Term Survivor, HIV Education and Advocacy Consultant, United States

Presentation | Audio

Oral Abstract Session 1: Pathways to Establishing and Maintaining HIV Latency


Invited Speaker: HIV-1 broadly neutralizing antibodies: Potential role in HIV treatment approaches

John Mascola, Vaccine Research Center, NIAID/NIH, United States

Presentation

OA1-1: CTLA-4-expressing memory CD4+ T-cells are critical contributors to SIV viral persistence
Colleen McGary, Emory University, United States

Abstract | Presentation | Audio

OA1-2: Molecular Determinants of HIV-1 Permissiveness and Persistence in Gut-Homing CD4+ T-Cells Expressing the Th17 Marker CCR6
Delphine Planas, CHUM-Research Center, University of Montreal, Canada

Abstract | Presentation | Audio

OA1-3: Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7
Jose Alcami, Instituto de Salud Carlos III, Spain

Abstract

OA1-4 LB: Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs
Jonathan Karn, Case Western Reserve University School of Medicine, United States

Abstract | Presentation | Audio

Roundtable: Advancing Paediatric HIV Cure Research


Audio

Chair: Jintanat Ananworanich, US Military HIV Research Program, United States

Panelists:
Marie Elizabeth Theunissen, FAMCRU, South Africa


Hugo Soudeyns, CHU Sainte-Justine Research Center and Université de Montréal, Canada

Presentation

Deborah Persaud, John Hopkins University, United States

Presentation

Ann Chahroudi, Emory University School of Medicine, United States

Presentation

Daria Hazuda, Merck, United States

Presentation

Oral Abstract Session 2: Activating Latent HIV Infection in vitro and in vivo


Invited Speaker: Immune recognition following latency reversal
Marcus Altfeld, Heinrich-Pette Institute, Leibniz Institute for Experimental Virology, Germany

Presentation | Audio

OA2-1: Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA - implications for virus production
Talia Mota, University of Melbourne, Peter Doherty Institute, Australia

Abstract | Presentation | Audio

OA2-2: Latency reversal Agent (LRA) Romidepsin Reactivates Latent Virus in Two Rhesus Macaque (RM) Models of Controlled SIV Infection in the Absence of Antiretroviral Therapy (ART)
Benjamin Policicchio, University of Pittsburgh, United States

Abstract | Presentation | Audio

OA2-3: Vorinostat, Panobinostat, and Romidepsin Nonselectively Activate Transcription from Quiescent HIV-1 Proviruses in HIV-infected Individuals on Long-term Suppressive Anti-retroviral Therapy
Kirston Barton, University of Sydney, Westmead Millennium Institute, Australia

Abstract | Presentation | Audio

OA2-4: Modulation of HERV family expression after treatment with HDAC inhibitors
Miguel de Mulder Rougvie, George Washington University, United States

Abstract

OA2-5: Ingenol Efficiently Reactivates Latent HIV in cells from aviremic patients
Vicente Planelles, University of Utah, United States

Abstract | Presentation | Audio

OA2-6 LB: CD4 Mimetics Sensitize HIV-1-Infected Cells to ADCC
Andres Finzi, The CHUM Research Center, University of Montreal & McGill University, Canada

Abstract | Presentation | Audio

Roundtable: Combination Therapy Trials


Audio

Chair: Daniel Kuritzkes, Brigham & Women’s Hospital, Harvard Medical School, United States

Panelists:
Brigitte Autran, Hôpital Pitié Salpêtrière, CIMI-Paris, UPMC/INSERM U1135, France

Presentation

Joseph Eron, University of North Carolina, United States

Presentation

Irina Tcherepanova, Argos Therapeutics, Inc., United States

Presentation

Jeffrey Lifson, Frederick National Laboratory for Cancer Research, United States

Presentation

David Evans, Project Inform, United States

Presentation

Oral Abstract Session 3: Novel Strategies to Identify and Quantify Virus Persistence in vivo (Biomarkers)


Invited Speaker: Engineering T cells to functionally cure HIV-1 infection
James Riley, Perelman School of Medicine, University of Pennsylvania, United States


OA3-1: Immunological Markers associated with HIV Persistence During ART Identified by Iterated Conditional Random Forests Analysis
Remi Fromentin, tyle="text-decoration: underline;">

Abstract | Presentation | Audio

OA3-2: Patient-derived defective HIV-1 proviruses containing large internal deletions can be transcribed and translated
Ross Pollack, The Johns Hopkins University School of Medicine, United States

Abstract | Presentation | Audio

OA3-3: Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T-cell count at 96 weeks ART
Alexander Pasternak, Academic Medical Center of the University of Amsterdam, Netherlands

Abstract | Presentation | Audio

OA3-4: Distinct HIV Genetic Populations in Effector Memory T-cells after Prolonged Therapy
Eunok Lee, Westmead Millennium Institute for Medical Research, University of Sydney, Australia

Abstract | Presentation | Audio

OA3-5 LB: Investigating the Role of the Immune Checkpoint Receptor TIGIT in T cells during HIV Disease Progression and as a Target for Immune Restoration
Glen Chew, University of Hawaii, United States

Abstract


Oral Abstract Session 4: Immunology and Persistence


Invited Speaker: CHERUB: Collaboration in HIV Eradication in the UK; Predictors of PTC and Viral Reactivation Strategies
Sarah Fidler, Imperial College London, United Kingdom

Presentation | Audio

OA4-1: Trancriptomics and Metabolomics identify inflammatory profiles that segregate subjects with High and Low inducible HIV reservoir
Khader Ghneim, Case Western Reserve University, United States

Abstract | Presentation | Audio

OA4-2: Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaques
Mirko Paiardini, Emory University, United States

Abstract | Presentation | Audio

OA4-3: Zinc Finger Nuclease Gene Editing for Functional Cure in a Nonhuman Primate Model of HIV/AIDS
Christopher Peterson, Fred Hutchinson Cancer Research Center, United States

Abstract | Presentation | Audio

OA4-4 LB: HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child
Asier Saez-Cirion, Institut Pasteur, France

Abstract | Presentation | Audio

OA4-5 LB: A Novel Therapeutic HIV-1 Vaccine Trial in Patients under HAART
Frank Tung, GeneCure Biotechnologies, United States

Abstract | Presentation | Audio

Roundtable: Key Partnerships: Community & Private Sector


Audio

Chair: Sharon Lewin, Doherty Institute, The University of Melbourne, Australia

Panelists:
David Margolis, University of North Carolina at Chapel Hill, United States

Presentation

Andrew Spaltenstein, GlaxoSmithKline, United States

Presentation

Lynda Dee, CARE CAB; AIDS Action Baltimore, United States

Presentation

Erik Iverson, Infectious Diseases Research Institute, United States

Presentation

Veronica Miller, UC Berkeley; Forum for HIV Collaborative Research, United States

Presentation

Closing  Session


Closing Lecture:  HBV Cure: Possible Lessons for HIV-AIDS
Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia

Presentation | Audio

IAS/ANRS HIV Cure Young Investigator Award Ceremony

Reverse transcription and integration

PE1: Primary resistance against dolutegravir decreases HIV integration
Thibault Mesplède, McGill University AIDS Centre, Lady Davis Institute for Medical Research – Jewish General Hospital, Canada

Abstract

PE2: HIV-1 integrase variants retarget proviral integration and are associated with disease progression
Rik Gijsbers, KU Leuven University, Belgium

Abstract

Intrinsic cellular defences and restriction factors

PE3: HIV-1 Vpu exploits the crosstalk between BST2 and the ILT7 receptor to inhibit innate sensing of infected T-cells by plasmacytoid dendritic cells
Éric A. Cohen, Institut de Recherches Cliniques de Montréal & Université de Montréal, Canada

Abstract | Poster

PE4: Decreased interferon signature in HIV-1 viremic controllers
Rui Andre Raposo, George Washington University, United States

Abstract

PE5: Differential effects of cell-surface CD4 and tetherin on ADCC mediated by non-neutralizing and broadly neutralizing anti-HIV antibodies: the role of Nef and Vpu
Tram Ngoc Quynh Pham, Institut de Recherches Cliniques de Montréal, Canada

Abstract

Type I Interferons (viral inhibition, immunomodulatory functions)

PE6: Comparison of gene expression profile between human and macaque dendritic cells infected with virus carrying or not Vpx-loaded particles and assessment of their pathogenic impact
Esther Calonge, Centro Nacional Microbiologia, ISCII, Spain

Abstract

Viral mechanisms of HIV/SIV persistence and latency

PE7: Low frequency of HIV rebound after antiretroviral treatment interruption
Miles Davenport, UNSW Australia, Australia

Abstract | Poster

PE8: Purging HIV-1 from latent reservoirs using human methyltransferase inhibitors
Sadia Samer, Federal University of Sao Paulo, Brazil

Abstract | Poster

Host cellular factors and latency

PE9: Transcriptional profiling identifies RORC and PPARG as two major mechanisms regulating HIV permissiveness in primary Th17 cells
Yuwei Zhang, CHUM Research Centre, Université de Montréal, Canada

Abstract | Poster

Cellular and tissue reservoirs of HIV/SIV

PE10: Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T-cells
Salma Jaafoura, INSERM U 1012, France

Abstract | Poster

PE11: Quantification and replication competency of HIV-1 following latency disruption in CD4+ T-cells
Jason Hataye, National Institute of Allergy and Infectious Disease, Vaccine Research Centre, United States

Abstract

PE12: T-cell immunity in testicular tissue of ART-treated HIV-infected subjects: results from the Orchid study
Mohammad-Ali Jenabian, Université du Québec á Montréal (UQAM), Canada

Abstract

PE13: Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages
Francesca Graziano, San Raffaele Scientific Institute, San Raffaele University, Milan

Abstract

Measurement of HIV/SIV reservoirs

PE14: Defining the Unique biomarkers of latently infected T-cells
Mudit Tyagi, George Washington University, United States

Abstract

PE15: Flow-based differentiation between latently HIV-1-infected single cells expressing Gag mRNA alone or in conjunction with Gag protein following latency reversal, Gloria Martrus
Heinrich-Pette-Institut Leibniz Institute for Experimental Virology, Germany

Abstract

PE16: HIV-1 transcription is stable during frequent longitudinal sampling in aviremic patients on ART: implications for HIV cure research
Steffen Leth, Aarhus University Hospital, Denmark

Abstract | Poster

PE17: Anti-HIV antibody responses reflect the quantifiable HIV reservoir size
Sulggi Lee, University of California, San Francisco, United States

Abstract | Poster

PE18:  Improved assays to measure the inducible latent HIV reservoir
Marta Massanella, UCSD, United States

Abstract

PE19 LB:  Time associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy - implications for clinical trials of cure interventions
Christina Chang, The University of Melbourne & Alfred Hospital, Australia

Abstract

PE20 LB:  Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencing
Sook-Kyung Lee, University of North Carolina, United States

Abstract | Poster

HIV-1 controllers (including post-treatment controllers)

PE21: Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4 T-cells in nonprogressors
Giovanna Rappocciolo, University of Pittsburgh, United States

Abstract

Asymptomatic long term non-progression

PE22: Characterization of anti-gp41 antibodies eliciting viral neutralization and protecting against CD4 depletion in long-term non-progressors
Patrice Debré, CIMI-Paris, INSERM U 1135, France

Abstract

PE23: CD40L-induced tunneling nanotube networks facilitate proinflammatory dendritic cell-mediated HIV-1 trans-infection of CD4+ T-cells
Colleen Zaccard, University of Pittsburgh, United States

Abstract | Poster

Targeting HIV persistence during ART (cure strategies)

PE24: MG1 and VSVΔ51 viruses target and kill latently HIV-infected myeloid cells
Nischal Ranganath, University of Ottowa, Canada

Abstract | Poster

PE25: Minimal HIV-1 Gag epitope presentation in a T-cell line during reactivation
Xiaomei Tallie Kuang, Simon Fraser University, Canada

Abstract

PE26: Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replication
Monique Nijhuis, University Medical Center Utrecht, Netherlands

Abstract

PE27: Anti-HIV CAR+ lymphocytes protected from HIV-infection by CCR5 disruption as a strategy to cure HIV
Thor Wagner, University of Washington & Seattle Children’s Research Institute, United States

Abstract

PE28:  Universal Tre-recombinase (uTre) specifically targets the majority of primary HIV-1 isolates
Joachim Hauber, Heinrich Pette Institute & German Center for Infection Research (DZIF), Germany

Abstract

PE29:  Polyvalent immune responses correlate with lower number of HIV infected CD4 T-cells in chronically infected subjects treated with autologous RNA pulsed DC therapy
Irina Tcherepanova, Argos Therapeutics Inc., United States

Abstract

PE30:  HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV rebound
Adam Capoferri, Howard Hughes Medical Institute & Johns Hopkins University, United States

Abstract | Poster

PE31: Robust HIV-specific T-cells in post-treatment controllers from the VISCONTI cohort
Brigitte Autran, Université Pierre et Marie Curie, Sorbonne Universités & Pitié-Salpétrière, C. Foix University Hospital, AP-HP, France

Abstract

PE32: Nef inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1
Eileen Scully, Ragon Institute of MGH, MIT and Harvard, Brigham & Women’s Hospital, United States

Abstract

PE33:  HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expression
Damian Purcell, University of Melbourne, Australia

Abstract

PE34:  Type-1 programmed dendritic cells induce primary CTL capable of effectively targeting the HIV-1 reservoir
Robbie B. Mailiiard, University of Pittsburgh, United States

Abstract

PE35:  Predictive pharmacodynamics model of transgene delivery for curative HIV gene therapy
Pavitra Roychoudhury, Fred Hutchinson Cancer Research Center, United States

Abstract | Poster

PE36 LB: Novel activators of latent HIV-1 from natural products
Ian Tietjen, Simon Fraser University & University of British Colombia, Canada

Abstract

PE37 LB: Protective HLA alleles fail to predict immune control of HIV after ART interruption in chronically infected patients with low HIV-DNA from the ULTRASTOP Study
Chiraz Hamimi, Sorbonne Universités & INSERM, UMR-S 1135, France

Abstract

PE38 LB: Reversal of HIV-1 latency by activation of patient-derived CD4+T-cells results in clonal expansion and sustained production of infectious virus from a subset of cells
John Bui, University of Pittsburgh & Howard Hughes Medical Institute, United States

Abstract | Poster

Novel approaches in immunotherapeutics (including bnAbs and anti-inflammatory mediators)

PE39: Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope
Kazuki Tanaka, Matsushita Project Laboratory, Japan

Abstract | Poster

PE40: A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T-cells ex vivo
Rasmus Offersen, Aarhus University Hospital, Denmark

Abstract

PE41: Treatment with anti-α4β7 integrin antibody reduces virus-mediated gastrointestinal pathology by targeting distinct mucosal tissues
Siddappa Byrareddy, Emory University, United States

Abstract

PE42 LB: Novel CD4-based bispecific chimeric antigen receptors provide potent and targeted killing of HIV-infected cells: a potential functional cure strategy
Barna Dey, National Institutes of Health, United States

Abstract

Therapeutic vaccines

PE43: Monocyte-derived DC electroporated with mRNAs encoding both specific HIV antigens and DC adjuvants are able to improve T-cell functionality
Felipe García, Hospital Clinic, IDIBAPS, University of Barcelona, Spain

Abstract | Poster

PE44: Therapeutic conserved elements (CE) DNA vaccine increases T-cell responses against highly conserved viral sequences in the setting of pre-existing immunodominant responses induced by chronic viral infection
Paul Munson, University of Washington, United States

Abstract

PE45: Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys
Ma Luo, National Microbiology Laboratory & University of Manitoba, Canada

Abstract

PE46: Safety and immunogenicity of ChAd.HIVconsv and MVA.HIVconsv therapeutic vaccines in a cohort of early treated HIV-1 infected individuals
Beatriz Mothe, IrsiCaixa AIDS Research Institute – HIVACAT, Fundació Lluita contra la Sida & UVic-UCC, Spain

Abstract | Poster

PE47: Development of a latency reversing activator vaccine (ACT-VEC) platform for HIV-1 cure therapy
Jamie F. S. Mann, University of Western Ontario, Canada

Abstract

PE48: Broadly specific, cytolytic T cell responses and lower inflammatory responses correlate with durable viral remission following therapuetic DNA vaccination in SIV-infected macaques
Deborah Fuller, University of Washington & Washington National Primate Research Center, United States

Abstract

Novel animal/virus models for vaccine, cure research, and inhibitor development

PE49: Crispr/Cas9 gene editing eradicates latent and protects cells against new HIV-1 infection
Kamel Khalili, Temple University, United States

Abstract | Poster

Acute and early infection

PE50: High rates of non-reactive HIV serology after antiretroviral treatment initiated in acute HIV infection
James L. K. Fletcher, SEARCH, The Thai Red Cross AIDS Research Centre, Thailand

Abstract |Poster

PE51 LB: Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to reducing CD8 T-cell elevation: Relevance for clinical outcome
Wei Cao, McGill University Health Center, United States & Peking Union Medical College Hospital, China

Abstract | Poster

PE52 LB: HIV reservoirs in semen at the time of Primary infection
Antoine Chéret, Bicêtre Hospital, AP-HP & Paris Descartes University, France

Abstract | Poster

PE53 LB: CD4/CD8 ratio at ART initiation as a predictor of viral rebound following interruption of ART initiated in primary HIV infection
John Thornhill, Imperial College London, United Kingdom

Abstract | Poster

Long-term non-progressors and elite controllers

PE54: Ultrastop: Is remission achievable in HIV-1 patients with low HIV DNA reservoir?
Christine Katlama, AP-HP Department of Infectious Diseases, Pitié-Salpêtrière University Hospital, Sorbonne Universités & INSERM, UMR_S 1136, France

Abstract | Poster

Timing of therapy initiation

PE55: Initiation of Antiretroviral Therapy at high CD4 cell counts is associated with Increased Adherence, Viral Suppression, and Decreased HIV Drug Resistance in British Columbia, Canada
Viviane D. Lima, British Colombia Centre for Excellence in HIV/AIDS, Canada

Abstract

PE56: Long-term early antiretroviral therapy limits the HIV-1 reservoir size as compared to later treatment initiation but not to levels found in long-term non-progressors
Eva Malatinkova, Ghent University and University Hospital Ghent, Belgium

Abstract | Poster

Ethical issues in clinical trials and treatment strategies

PE57: Proposed HIV cure research in South Africa: perspectives of HIV researchers, clinicians and advocates on the anticipated ethical challenges
Keymanthri Moodley, Stellenbosch University, Centre for Medical Ethics and Law, South Africa

Abstract

PE58: The ethics of HIV cure clinical research among acutely infected adults: points for consideration
Adam Lloyd Gilbertson, University of North Carolina at Chapel Hill, United States & University of Oxford, United Kingdom

Abstract | Poster

Therapeutic vaccine trials

PE59: HIV-1 reservoir dynamics after vaccination and antiretroviral therapy interruption are driven by dendritic cell-vaccine induced T-cell responses
Felipe García<, Hospital Clinic, IDIBAPS, University of Barcelona, Spain

Abstract | Poster

PE60: Patient-reported receptiveness to a HIV therapeutic vaccine
David Zucman, Centro Medico Chirurgical Foch, France

Abstract | Poster

PE61: Vacc-4x/lenalidomide increases naïve CD4 T-cells in well controlled patients on ART with low preART CD4 counts and poor immune reconstitution
Jan van Lunzen, University Medical Center Hamburg-Eppendorf, Germany

Abstract

PE62 LB: A first-in-human phase I/II trial demonstrates the safety and the immunogenicity of a lentiviralbased therapeutic HIV vaccine eliciting potent polyfunctional multispecific CD8 and CD4 Tcell responses in HIV-infected individuals
Hélène Toussaint, Theravectys, France

Abstract |Poster

Complementary and traditional medicines

PE63: “Hard” versus “Soft” HIV Cure: an Anthropological investigation of the
Cultural Meaning of HIV Cure in China
Qingyan Ma, University of North Carolina Project-China & Guangzhou No. Eight People’s Hospital China

Abstract | Poster

Curative interventions (including those aimed at reservoir depletion)

PE64: Reduction in total HIV-1 proviral DNA following re-boost immunizations using the peptide-based therapeutic vaccine candidate, Vacc-4x, during ART
Maja A. Sommerfelt, Bionor Pharma ASA, Norway

Abstract

PE65: Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-infected individuals
Ayla Cash, Johns Hopkins University, United States

Abstract | Poster

Novel therapeutic approaches (including gene therapy)

PE66: VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IPROTECT1 multicenter European study
Christine Katlama, AP-HP Pitie Salperiere Hospital & INSERM, France

Abstract

PE67 LB: VAC-3S, a safe Immunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD8 ratio: Phase I Final Results
Raphaël Ho Tsong Fang, InnaVirVax, France

Abstract | Poster

PE68 LB: Perspectives on the acceptability of HCRC trials: the challenges for physicians and PLWHIV (ANRS APSEC)
Bruno Spire, INSERM U912 SESSTIM, Aix Marseille Université & ORS PACA, France

Abstract | Poster

Clinical trials and antiretroviral therapy in children and adolescents

PE69 LB: Low but Detectable IFN-γ Responses against Clade-Matched HIV-1 Peptides in Early-Treated Vertically-Infected Children with Long-Term Sustained Viral Suppression
Hinatea Dieumegard, Centre de recherché du CHU Saint-Justine & Université de Montréal, Canada

Abstract | Poster

Engagement of community in service delivery

PE70: Results of a community needs assessment and pilot test of a novel HIV cure research training curriculum
Karine Dubé, UNC-Chapel Hill, Collaboratory of AIDS Researchers for Eradication (CARE), United States

Abstract | Poster

PE71: Bringing community to cure
Laurie Sylla, Fred Hutchinson Cancer Research Center, defeatHIV Martin Delaney Collaboratory Community Advisory Board, United States

Abstract

PE72: Planning and Community Engagement for HIV Cure Research in Canada, A Collaborative Program Between National Research Teams and Key Populations
Robert Reinhard, Institut de Recherches Cliniques de Montréal & Ontario HIV Treatment Network, Canada

Abstract | Poster

PE73: The transition from incurable to curable: Pediatric leukemia, psychological dimensions of new disease cures, and implications for HIV
Catherine Gliwa, University of California Los Angeles & University of North Carolina at Chapel Hill, United States

Abstract | Poster

PE74 LB: HIV cure goes viral: an analysis of HIV cure #hashtags
Kathryn Muessig, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, United States

Abstract | Poster

Photo gallery